CorMedix Inc (NASDAQ: CRMD) has reported E.P.S. of $-0.25 for its second fiscal quarter (ending June 30) versus $-0.25 for the same period a year ago. For the latest four quarters through June 30, E.P.S. were $-0.93 compared to $-0.86 a year ago.
Recent Price Action
On 8/14/24, CorMedix Inc (NASDAQ: CRMD) stock enjoyed a major increase of 30.2%, closing at $4.92. Moreover, exceptionally high trading volume at 529% of normal accompanied the advance. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 21.6% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, CRMD is expected to continue to be Value Creation neutral.
CorMedix has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. CorMedix has a very low Appreciation Score of 4 but a very high Power Rating of 92, producing the Neutral Value Trend Rating.
Rating Review
In light of this new information and very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment